News Releases

Date	Title
07/06/2021	Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™
07/01/2021	Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours
05/25/2021	Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference
05/25/2021	Heron Therapeutics Announces $150 Million Convertible Debt Financing
05/13/2021	Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
05/10/2021	Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate Updates
02/24/2021	Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
02/17/2021	Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences
01/21/2021	Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery
01/11/2021	Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

Keyword Search